Consistent findings from both in vitro and in vivo experiments demonstrated that depletion of TXNDC12 diminished malignant phenotypes and reduced cisplatin resistance in HNSCC cells. This evidence concerns the gene TXNDC12 and head and neck squamous cell carcinoma.